FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer By Ogkologos - February 6, 2025 374 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eXALT3 study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR How Joining a Clinical Trial Helped Me Find Hope While Living... December 5, 2023 Leading Change in Cancer Clinical Research, Because Our Patients Can’t Wait May 31, 2024 Get to Know CaringBridge June 3, 2021 First targeted treatment approved for advanced prostate cancer on NHS in... October 13, 2021 Load more HOT NEWS At 3-Year Follow-Up Nivolumab Plus Chemotherapy Continued to Demonstrate OS Improvement... Georgia Middle Schooler Donates All the Proceeds of Her Grand Champion... The Opioid Epidemic and Cancer Pain Management: A Conversation with Dr.... Higher Risk of Invasive Behaviour for Oncogenic Fusions–Driven Paediatric Thyroid Cancers
